** Shares of drugmaker Emergent Biosolutions EBS.N rise 2.9% to $6.40 premarket
** EBS says U.S. Department of Health and Human Services has awarded it $62.4 million through contract modification to stockpile co's botulism treatment
** Modification has been made to existing 10-year contract whereby co will supply treatment called BAT
** Up to last close, stock had fallen 34.9% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.